Smith & Nephew SNATS (NYSE:SNN) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Smith & Nephew SNATS (NYSE:SNN – Free Report) from a buy rating to a strong-buy rating in a research note published on Saturday.

Separately, Canaccord Genuity Group increased their price target on Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a “hold” rating in a research report on Monday, August 18th. Six equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $36.00.

View Our Latest Analysis on SNN

Smith & Nephew SNATS Trading Up 0.7%

NYSE SNN opened at $37.47 on Friday. The firm has a market capitalization of $16.41 billion, a PE ratio of 17.35, a price-to-earnings-growth ratio of 1.03 and a beta of 0.70. Smith & Nephew SNATS has a one year low of $23.69 and a one year high of $37.65. The company has a 50-day simple moving average of $32.98 and a 200-day simple moving average of $29.78. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00.

Smith & Nephew SNATS Cuts Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 3rd will be given a $0.285 dividend. This represents a yield of 210.0%. The ex-dividend date is Friday, October 3rd. Smith & Nephew SNATS’s dividend payout ratio (DPR) is currently 41.20%.

Institutional Investors Weigh In On Smith & Nephew SNATS

A number of hedge funds and other institutional investors have recently modified their holdings of SNN. Bank of Montreal Can grew its position in Smith & Nephew SNATS by 321.6% in the 2nd quarter. Bank of Montreal Can now owns 3,429,829 shares of the medical equipment provider’s stock valued at $105,056,000 after buying an additional 2,616,301 shares in the last quarter. River Road Asset Management LLC lifted its stake in shares of Smith & Nephew SNATS by 9.3% in the 2nd quarter. River Road Asset Management LLC now owns 3,179,814 shares of the medical equipment provider’s stock worth $97,175,000 after acquiring an additional 270,480 shares during the period. Scharf Investments LLC boosted its holdings in shares of Smith & Nephew SNATS by 0.3% in the second quarter. Scharf Investments LLC now owns 2,083,513 shares of the medical equipment provider’s stock valued at $63,818,000 after acquiring an additional 6,993 shares in the last quarter. J. Goldman & Co LP acquired a new position in shares of Smith & Nephew SNATS during the fourth quarter valued at approximately $47,700,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Smith & Nephew SNATS by 49.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock worth $50,255,000 after buying an additional 583,809 shares in the last quarter. 25.64% of the stock is currently owned by institutional investors.

Smith & Nephew SNATS Company Profile

(Get Free Report)

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

Featured Stories